165 related articles for article (PubMed ID: 36343426)
1. Grey matter morphology in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
Kaltsouni E; Dubol M; Wikström J; Lanzenberger R; Sundström-Poromaa I; Comasco E
Eur Neuropsychopharmacol; 2022 Dec; 65():35-43. PubMed ID: 36343426
[TBL] [Abstract][Full Text] [Related]
2. Grey matter correlates of affective and somatic symptoms of premenstrual dysphoric disorder.
Dubol M; Wikström J; Lanzenberger R; Epperson CN; Sundström-Poromaa I; Comasco E
Sci Rep; 2022 Apr; 12(1):5996. PubMed ID: 35397641
[TBL] [Abstract][Full Text] [Related]
3. White matter volume and treatment with selective progesterone receptor modulator in patients with premenstrual dysphoric disorder.
Kaltsouni E; Wikström J; Lanzenberger R; Sundström-Poromaa I; Comasco E
Psychoneuroendocrinology; 2024 May; 163():106977. PubMed ID: 38295626
[TBL] [Abstract][Full Text] [Related]
4. Cortical morphology variations during the menstrual cycle in individuals with and without premenstrual dysphoric disorder.
Dubol M; Stiernman L; Sundström-Poromaa I; Bixo M; Comasco E
J Affect Disord; 2024 Jun; 355():470-477. PubMed ID: 38552916
[TBL] [Abstract][Full Text] [Related]
5. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
Kaltsouni E; Fisher PM; Dubol M; Hustad S; Lanzenberger R; Frokjaer VG; Wikström J; Comasco E; Sundström-Poromaa I
Neuropsychopharmacology; 2021 Jul; 46(8):1460-1467. PubMed ID: 33927343
[TBL] [Abstract][Full Text] [Related]
6. Differential grey matter structure in women with premenstrual dysphoric disorder: evidence from brain morphometry and data-driven classification.
Dubol M; Stiernman L; Wikström J; Lanzenberger R; Neill Epperson C; Sundström-Poromaa I; Bixo M; Comasco E
Transl Psychiatry; 2022 Jun; 12(1):250. PubMed ID: 35705554
[TBL] [Abstract][Full Text] [Related]
7. Treatment of premenstrual dysphoric disorder with the GABA
Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
[TBL] [Abstract][Full Text] [Related]
8. New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder.
Sundström-Poromaa I; Comasco E
CNS Drugs; 2023 May; 37(5):371-379. PubMed ID: 37171547
[TBL] [Abstract][Full Text] [Related]
9. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.
Comasco E; Kopp Kallner H; Bixo M; Hirschberg AL; Nyback S; de Grauw H; Epperson CN; Sundström-Poromaa I
Am J Psychiatry; 2021 Mar; 178(3):256-265. PubMed ID: 33297719
[TBL] [Abstract][Full Text] [Related]
10. Estrogen, progesterone, cortisol, brain-derived neurotrophic factor, and vascular endothelial growth factor during the luteal phase of the menstrual cycle in women with premenstrual dysphoric disorder.
Ko CH; Wong TH; Suen JL; Lin PC; Long CY; Yen JY
J Psychiatr Res; 2024 Jan; 169():307-317. PubMed ID: 38070471
[TBL] [Abstract][Full Text] [Related]
11. Early- and Late-Luteal-Phase Estrogen and Progesterone Levels of Women with Premenstrual Dysphoric Disorder.
Yen JY; Lin HC; Lin PC; Liu TL; Long CY; Ko CH
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31703451
[No Abstract] [Full Text] [Related]
12. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.
Bixo M; Johansson M; Timby E; Michalski L; Bäckström T
J Neuroendocrinol; 2018 Feb; 30(2):. PubMed ID: 29072794
[TBL] [Abstract][Full Text] [Related]
13. GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder.
Miller KN; Standeven L; Morrow AL; Payne JL; Epperson CN; Hantsoo L
Psychoneuroendocrinology; 2024 Feb; 160():106684. PubMed ID: 38091917
[TBL] [Abstract][Full Text] [Related]
14. Aberrant Intrinsic Brain Network Functional Connectivity During a Face-Matching Task in Women Diagnosed With Premenstrual Dysphoric Disorder.
Reuveni I; Dan R; Canetti L; Bick AS; Segman R; Azoulay M; Kalla C; Bonne O; Goelman G
Biol Psychiatry; 2023 Sep; 94(6):492-500. PubMed ID: 37031779
[TBL] [Abstract][Full Text] [Related]
15. Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.
Hantsoo L; Grillon C; Sammel M; Johnson R; Marks J; Epperson CN
Psychopharmacology (Berl); 2021 Oct; 238(10):2985-2997. PubMed ID: 34292344
[TBL] [Abstract][Full Text] [Related]
16. GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder.
Sikes-Keilp C; Rubinow DR
CNS Drugs; 2023 Aug; 37(8):679-693. PubMed ID: 37542704
[TBL] [Abstract][Full Text] [Related]
17. Elevated gray matter volume of the emotional cerebellum in women with premenstrual dysphoric disorder.
Berman SM; London ED; Morgan M; Rapkin AJ
J Affect Disord; 2013 Apr; 146(2):266-71. PubMed ID: 22868063
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.
Bäckström T; Ekberg K; Hirschberg AL; Bixo M; Epperson CN; Briggs P; Panay N; O'Brien S
Psychoneuroendocrinology; 2021 Nov; 133():105426. PubMed ID: 34597899
[TBL] [Abstract][Full Text] [Related]
19. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study.
Epperson CN; Haga K; Mason GF; Sellers E; Gueorguieva R; Zhang W; Weiss E; Rothman DL; Krystal JH
Arch Gen Psychiatry; 2002 Sep; 59(9):851-8. PubMed ID: 12215085
[TBL] [Abstract][Full Text] [Related]
20. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
Yonkers KA; Kornstein SG; Gueorguieva R; Merry B; Van Steenburgh K; Altemus M
JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
